[Comment] Phage therapy 2.0: where do we stand?

22:40 EDT 3 Oct 2018 | The Lancet

In The Lancet Infectious Diseases, Patrick Jault and colleagues1 report the results of the PhagoBurn study investigating the efficacy and tolerability of a cocktail of bacteriophages against Pseudomonas aeruginosa in infected burn wounds.

Original Article: [Comment] Phage therapy 2.0: where do we stand?

More From BioPortfolio on "[Comment] Phage therapy 2.0: where do we stand?"